Purpose Polyamorphism, the existence of two amorphous phases related by a first-order transition, is an important phenomenon in the of amorphous materials, but remains poorly understood, even controversial. As amorphous solids are explored for the delivery poorly soluble drugs, polyamorphism could offer an additional tool to engineer the property of materials. At present only three molecular systems are reported to exhibit polyamorphism. We investigate the possibility that the common pharmaceutical exc mannitol may exhibit this phenomenon. Methods A suspected second amorphous phase of D-mannitol (Phase X) was prepared by annealing the known amorphous phase just ab glass transition temperature T g . Phase X was characterized by XRD, Raman spectroscopy, DSC, and Flash DSC. Heat capacity measured with Modulated DSC. Results Slightly above T g (284 K), the supercooled liquid (SCL) of D-mannitol transforms to a low-energy, apparently amorphous pha (Phase X) with stronger hydrogen bonds. The enthalpy of Phase X is approximately halfway between those of the known amo and crystalline phases. Similar to the SCL, Phase X is transparent with broad X-ray diffraction and Raman scattering; upon temperature cycling, it exhibits a glass-transition-like change of heat capacity. On fast heating, Phase X transforms back to the near T g + 50 K. The presence of D-sorbitol enables observation of a first-order liquid-liquid transition from the SCL to Phase X Conclusion The common drug excipient D-mannitol may have two amorphous phases related by a reversible, first-order transition. The tra from SCL to Phase X has intriguing similarities with polyamorphic transitions reported for triphenyl phosphite (TPP) and wat is the first report of possible polyamorphism for a substance of pharmaceutical relevance.
